Abstract 111P
Background
Immunohistochemistry (IHC)/in situ hybridization (ISH) are widely used methods in many pathology laboratories to assess human epidermal growth factor receptor 2 (HER2) status in gastric cancer (GC) patients. Nowadays, next generation sequencing (NGS) technologies are adopted to precisely predict absolute gene amplification levels. However, these tissue-based tests are suffering from intratumoral heterogeneity and inter-laboratory technical biases.
Methods
We set up a novel probe-based Absolute Q digital PCR assays for quantitative measurement of HER2 amplification using the formalin-fixed paraffin embedded (FFPE) tissue samples and the results were compared with IHC/ISH and NGS results in 184 gastric adenocarcinoma samples. HER2 amplifications were determined with HER2 TaqMan® probe hydrolysis assays within exon 22 and was multiplexed by the ratios of HER2 copy number (CN) to reference gene CN (HER2/RNaseP ratio).
Results
With digital PCR, the median HER2 CN were 1.79 copies/μL (ranged from 0.02 to 48.87 copies/μL). With NGS, HER2 amplifications were detected in 28 cases (15.2%). By IHC, HER2 positive (3+) was found in 25 cases (13.6%) and equivocal (2+) cases were observed in 15 cases (8.2%), in which ISH conformed amplifications in 13 cases. The concordance rate between IHC (3+ or 2+ and HER2 amplified) and NGS was 71.3%. In HER2-amplified cases by NGS, the median CN measured with digital PCR were 9.7 copies/μL (ranged from 1.95 to 48.87 copies/μL). In statistical analyses, Pearson correlation coefficients between NGS and digital PCR was 0.916, suggesting strong correlation. Given HER2 amplification by NGS as the standard reference, digital PCR predicted HER2 amplification with a 98.7% specificity, 92.9% sensitivity, 92.9% positive predictive value, and 98.7% negative predictive value. The AUC values for predicting HER2 amplification by digital PCR were 0.989.
Conclusions
With newly designed novel probes, digital PCR accurately measured HER2 CN with high sensitivity and specificity.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Ministry of Health & Welfare, Republic of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract